LEI:
549300Q7EXQQH6KF7Z84
6 August
2024
RTW Biotech Opportunities
Ltd
New Investment in Jade Biosciences,
Inc.
RTW Biotech Opportunities Ltd (the "Company"), a
London Stock Exchange-listed investment company focused on
identifying transformative assets with high growth potential across
the life sciences sector, is pleased to note the investment in new
portfolio company, Jade Biosciences, Inc. ("Jade").
The Company, alongside other
investment vehicles managed by RTW Investments, LP (the
"Investment Manager"),
participated in Jade's financing round that raised $80 million for
its launch. The funding will be used to support Jade's plans to
develop targeted therapies for indications with high unmet need
across inflammation and immunology.
Jade Biosciences is developing a
pipeline of potentially best-in-class therapies to redefine the
standard of care for patients living with autoimmune conditions.
Jade's pipeline of potentially best-in-class biologics was
engineered by Paragon
Therapeutics, which was founded by
leading healthcare investor Fairmount. Jade is the fourth company
founded from Paragon, which also includes Apogee Therapeutics,
whose Series B the Company also invested in and continues to hold
in its core public portfolio segment.
Josh Kennedy-Smith,
Partner and Research Analyst at
the Investment Manager said, "Jade Biosciences is an exciting new
biotech developing best-in-class therapies for autoimmune diseases.
We believe there is high potential and value in Jade's pipeline,
which aims to address significant unmet medical needs in immunology
and inflammation."
The full text of Jade's announcement can be
accessed on its website at:
https://jadebiosciences.com/.
For
Further Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
|
Charles Ryland
|
|
|
Henry Wilson
|
|
|
George Beale
|
|
|
Deutsche Numis (Joint Corporate Broker)
Freddie Barnfield
|
+44
20 7260 1000
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
|
David Harris
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44 14 8181 0100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
|
|
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********